Christian Schetter, formerly chief executive of Rigontec GmbH, has joined the life science investment group Arix Bioscience Plc as entrepreneur in residence. In this position he will advise Arix on investments and company creation. Dr Schetter led Rigontec until its acquisition by Merck & Co Inc in 2017. Before that, he was CEO of Neovii Biotech (previously Fresenius Biotech) where he helped bring a new antibody product to the market.
Dr Schetter received his undergraduate degree and PhD from the University of Cologne in Germany and did postdoctoral research in oncology and virology at the Scripps Research Institute in the US.
Arix Bioscience announced the appointment on 11 December 2018.
Copyright 2019 Evernow Publishing Ltd